You are viewing an incomplete version of our website. Please click to reload the website as full version.

ATP13A2 antibody (ATPase Type 13A2) (C-Term)

Details for Product anti-ATP13A2 Antibody No. ABIN950560, Supplier: Log in to see
Antigen
  • RGD1307977
  • ATP13A2
  • im:7147302
  • zgc:136762
  • CLN12
  • HSA9947
  • KRPPD
  • PARK9
  • 1110012E06Rik
  • AA589443
Epitope
C-Term, AA 1132-1161
13
13
3
2
2
1
1
1
1
1
1
Reactivity
Human
41
16
14
Host
Rabbit
37
6
Clonality
Polyclonal
Conjugate
This ATP13A2 antibody is un-conjugated
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
Application
Enzyme Immunoassay (EIA), Western Blotting (WB)
27
19
11
6
3
2
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Immunogen KLH conjugated synthetic peptide between 1132-1161 amino acids from the C-terminal region of human ATP13A2
Isotype Ig
Specificity This antibody reacts to ATP13A2.
Cross-Reactivity (Details) Species reactivity (tested):Human.
Purification Affinity chromatography on Protein A
Alternative Name ATP13A2 / PARK9 (ATP13A2 Antibody Abstract)
Background This gene encodes a member of the P5 subfamily of ATPases which transports inorganic cations as well as other substrates. Mutations in this gene are associated with Kufor-Rakeb syndrome (KRS), also referred to as Parkinson disease 9. Multiple transcript variants encoding different isoforms have been found for this gene.Synonyms: Probable cation-transporting ATPase 13A2
Gene ID 23400
NCBI Accession NP_001135446
Pathways
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Liquid
Concentration 0.25 mg/mL
Buffer PBS containing 0.09 % (W/V) sodium azide as preservative
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Supplier Images
Western Blotting (WB) image for anti-ATP13A2 antibody (ATPase Type 13A2) (C-Term) (ABIN950560) ATP13A2 Antibody (C-term) western blot analysis in U251 cell line lysates (35µg/lane)...
Background publications Dos Santos, Pestana, Diniz et al.: "Mutational analysis of GIGYF2, ATP13A2 and GBA genes in Brazilian patients with early-onset Parkinson's disease." in: Neuroscience letters, Vol. 485, Issue 2, pp. 121-4, 2010 (PubMed).

Reetz, Tadic, Kasten et al.: "Structural imaging in the presymptomatic stage of genetically determined parkinsonism." in: Neurobiology of disease, Vol. 39, Issue 3, pp. 402-8, 2010 (PubMed).

Schneider, Paisan-Ruiz, Quinn et al.: "ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation." in: Movement disorders : official journal of the Movement Disorder Society, Vol. 25, Issue 8, pp. 979-84, 2010 (PubMed).

Fei, Cao, Xiao et al.: "Lack of association between ATP13A2 Ala746Thr variant and Parkinson's disease in Han population of mainland China." in: Neuroscience letters, Vol. 475, Issue 2, pp. 61-3, 2010 (PubMed).

Okada, Kamatani, Takahashi et al.: "A genome-wide association study in 19 633 Japanese subjects identified LHX3-QSOX2 and IGF1 as adult height loci." in: Human molecular genetics, Vol. 19, Issue 11, pp. 2303-12, 2010 (PubMed).